TREATMENT OF THE MURINE, RETROVIRUS-INDUCED LYMPHOPROLIFERATIVE IMMUNODEFICIENCY DISEASE (LP-BM5) IN C57BL/10 MICE WITH THE IMMUNOMODULATOR IMEXON

被引：11

作者：

FUNK, CY

EISMAN, J

HERSH, EM

机构：

[1] ARIZONA CANC CTR,HEMATOL & ONCOL SECT,1501 N CAMPBELL AVE,TUCSON,AZ 85724

[2] UNIV MARYLAND,CTR CANC,DIV DEV THERAPEUT,BALTIMORE,MD 21201

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 1992年 / 8卷 / 05期

关键词：

D O I：

10.1089/aid.1992.8.633

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Imexon (4-imino-1, 3-diazabicyclo-(3.1.0)-hexan-2-one) a cyanoaziridine compound was studied in the treatment of the murine retrovirus-induced immunodeficiency disease model of AIDS (LP-BM5, MAIDS). Imexon, in dose-dependent fashion, partially prevented the development of hypergammaglobulinemia and splenomegaly, and partially prevented the decline in the phytohemagglutinin-induced proliferative response of spleen lymphocytes when started 1 or 15 days after virus inoculation. There was a statistically significant reduction in these disease-associated manifestations. When animals were treated starting 78 or 92 days after virus inoculation, lymphadenopathy was completely abrogated and survival was significantly prolonged in a dose-responsive manner. Since Imexon and other cyanoaziridine compounds have been safely administered to humans, we suggest that this class of compounds be further investigated in both large animal models of HIV infection and in patients with HIV-induced disease.

引用

页码：633 / 638

页数：6

共 18 条

[1] SEVERE IMMUNODEFICIENCY DISEASE INDUCED BY A DEFECTIVE MURINE LEUKEMIA-VIRUS [J].

AZIZ, DC ;

HANNA, Z ;

JOLICOEUR, P .

NATURE, 1989, 338 (6215) :505-508

[2]

Bicker U. W., 1984, IMMUNE MODULATION AG, P447

[3]

Bicker UF, 1978, IMMUNE MODULATION CO, P389

[4]

BILELLO JA, 1987, 3 INT C AIDS, P165

[5] ANTIVIRAL EFFICACY OF IMEXON IN THE RAUSCHER MURINE RETROVIRUS AIDS MODEL [J].

CHIRIGOS, MA ;

USSERY, MA ;

RANKIN, JT ;

HERRMANN, D ;

BICKER, U ;

BLACK, PL .

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1990, 12 (01) :1-21

[6] THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

FISCHL, MA ;

RICHMAN, DD ;

GRIECO, MH ;

GOTTLIEB, MS ;

VOLBERDING, PA ;

LASKIN, OL ;

LEEDOM, JM ;

GROOPMAN, JE ;

MILDVAN, D ;

SCHOOLEY, RT ;

JACKSON, GG ;

DURACK, DT ;

KING, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191

[7]

FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219

[8]

GROOPMAN JE, 1987, SEMIN ONCOL, V14, P1

[9] DITIOCARB SODIUM (DIETHYLDITHIOCARBAMATE) THERAPY IN PATIENTS WITH SYMPTOMATIC HIV-INFECTION AND AIDS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY [J].

HERSH, EM ;

BREWTON, G ;

ABRAMS, D ;

BARTLETT, J ;

GALPIN, J ;

GILL, P ;

GORTER, R ;

GOTTLIEB, M ;

JONIKAS, JJ ;

LANDESMAN, S ;

LEVINE, A ;

MARCEL, A ;

PETERSEN, EA ;

WHITESIDE, M ;

ZAHRADNIK, J ;

NEGRON, C ;

BOUTITIE, F ;

CARAUX, J ;

DUPUY, JM ;

SALMI, LR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (12) :1538-1544

[10] EFFECTIVE THERAPY OF THE LP-BM5 MURINE RETROVIRUS-INDUCED LYMPHOPROLIFERATIVE IMMUNODEFICIENCY DISEASE WITH DIETHYLDITHIOCARBAMATE [J].

HERSH, EM ;

FUNK, CY ;

RYSCHON, KL ;

PETERSEN, EA ;

MOSIER, DE .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (06) :553-561

← 1 2 →